Literature DB >> 11356848

Mullerian inhibiting substance regulates NFkappaB signaling and growth of mammary epithelial cells in vivo.

D L Segev1, Y Hoshiya, A E Stephen, M Hoshiya, T T Tran, D T MacLaughlin, P K Donahoe, S Maheswaran.   

Abstract

Müllerian inhibiting substance (MIS) inhibits breast cancer cell growth in vitro through interference with cell cycle progression and induction of apoptosis, a process associated with NFkappaB activation and up-regulation of one of its important target genes, IEX-1S (Segev, D. L., Ha, T., Tran, T. T., Kenneally, M., Harkin, P., Jung, M., MacLaughlin, D. T., Donahoe, P. K., and Maheswaran, S. (2000) J. Biol. Chem. 275, 28371-28379). Here we demonstrate that MIS activates the NFkappaB signaling cascade, induces IEX-1S mRNA, and inhibits the growth of MCF10A, an immortalized human breast epithelial cell line with characteristics of normal cells. In vivo, an inverse correlation was found to exist between various stages of mammary growth and MIS type II receptor expression. Receptor mRNA significantly diminished during puberty, when the ductal system branches and invades the adipose stroma and during the expansive growth at lactation, but it was up-regulated during involution, a time of regression and apoptosis. Peripartum variations in MIS type II receptor expression correlated with NFkappaB activation and IEX-1S mRNA expression. Administration of MIS to female mice induced NFkappaB DNA binding and IEX-1S mRNA expression in the breast. Furthermore, exposure to MIS in vivo increased apoptosis in the mouse mammary ductal epithelium. Thus, MIS may function as an endogenous hormonal regulator of NFkappaB signaling and growth in the breast.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11356848     DOI: 10.1074/jbc.M103092200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Anti-Müllerian hormone concentrations in premenopausal women and breast cancer risk.

Authors:  Hazel B Nichols; Donna D Baird; Frank Z Stanczyk; Anne Z Steiner; Melissa A Troester; Kristina W Whitworth; Dale P Sandler
Journal:  Cancer Prev Res (Phila)       Date:  2015-04-14

2.  Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts.

Authors:  Wenzhen Ge; Tess V Clendenen; Yelena Afanasyeva; Karen L Koenig; Claudia Agnoli; Louise A Brinton; Joanne F Dorgan; A Heather Eliassen; Roni T Falk; Göran Hallmans; Susan E Hankinson; Judith Hoffman-Bolton; Timothy J Key; Vittorio Krogh; Hazel B Nichols; Dale P Sandler; Minouk J Schoemaker; Patrick M Sluss; Malin Sund; Anthony J Swerdlow; Kala Visvanathan; Mengling Liu; Anne Zeleniuch-Jacquotte
Journal:  Int J Cancer       Date:  2018-02-08       Impact factor: 7.396

3.  Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance.

Authors:  Elizabeth J Renaud; David T MacLaughlin; Esther Oliva; Bo R Rueda; Patricia K Donahoe
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-23       Impact factor: 11.205

4.  Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model.

Authors:  V Gupta; J L Carey; H Kawakubo; A Muzikansky; J E Green; P K Donahoe; D T MacLaughlin; S Maheswaran
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-22       Impact factor: 11.205

5.  Plasma Anti-Müllerian Hormone Concentrations and Risk of Breast Cancer among Premenopausal Women in the Nurses' Health Studies.

Authors:  A Heather Eliassen; Anne Zeleniuch-Jacquotte; Bernard Rosner; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-03-09       Impact factor: 4.254

6.  HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis.

Authors:  Tetsu Hayashida; Fumiyuki Takahashi; Naokazu Chiba; Elena Brachtel; Motomi Takahashi; Nadia Godin-Heymann; Kenneth W Gross; Maria d M Vivanco; Vasuki Wijendran; Toshihiro Shioda; Dennis Sgroi; Patricia K Donahoe; Shyamala Maheswaran
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-28       Impact factor: 11.205

7.  Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107.

Authors:  Thanh U Barbie; David A Barbie; David T MacLaughlin; Shyamala Maheswaran; Patricia K Donahoe
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-11       Impact factor: 11.205

8.  Regulation of gonadotropin gene expression by Mullerian inhibiting substance.

Authors:  Grégoy Y Bédécarrats; Francis H O'Neill; Errol R Norwitz; Ursula B Kaiser; Jose Teixeira
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-23       Impact factor: 11.205

9.  The anti-Müllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand.

Authors:  Imed Salhi; Sylvie Cambon-Roques; Isabelle Lamarre; Daniel Laune; Franck Molina; Martine Pugnière; Didier Pourquier; Marian Gutowski; Jean-Yves Picard; Françoise Xavier; André Pèlegrin; Isabelle Navarro-Teulon
Journal:  Biochem J       Date:  2004-05-01       Impact factor: 3.857

10.  Prospective case-control study of serum mullerian inhibiting substance and breast cancer risk.

Authors:  Joanne F Dorgan; Frank Z Stanczyk; Brian L Egleston; Lisa L Kahle; Christiana M Shaw; Cynthia S Spittle; Andrew K Godwin; Louise A Brinton
Journal:  J Natl Cancer Inst       Date:  2009-10-09       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.